ArticleCurrent neuropharmacology2026

Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase.

Aurora Zanghì et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.